Abstract: The present invention aims to provide an inorganic substance-laminated sheet that can be used suitably for applications that require high gas barrier properties. The inorganic substance-laminated sheet includes a sheet having a dispersed structure with a structural period of 0.001 ?m to 100 ?m on at least one surface and an inorganic substance layer covering the surface having the dispersed structure.

Abstract: There is provided a platy Mg-containing zinc oxide sintered compact containing 1 to 10 wt % Mg as a first dopant element and 0.005 wt % or more at least one second dopant element selected from the group consisting of Al, Ga and In, the balance consisting essentially of ZnO and optionally at least one third dopant element selected from the group consisting of Br, Cl, F, Sn, Y, Pr, Ge, B, Sc, Si, Ti, Zr, Hf, Mn, Ta, W, Cu, Ni, Cr, La, Gd, Bi, Ce, Sr and Ba, wherein the (002)-plane or (100)-plane orientation in the plate surface is 60% or more. The Mg-containing zinc oxide sintered compact of the present invention has excellent properties such as high orientation despite solid dissolution of Mg.

Abstract: A green body for a cross-hole, compacted cutting insert, as well as a cutting insert, equipment for making a green body, and method for making a green body, wherein the green body includes a first side, a second side, and a side surface extending between the first side and the second side entirely around the first side and the second side. The green body includes a quadrilateral-shaped cross-hole extending through the green body from a first location on the side surface to a second location on the side surface on an opposite side of the green body from the first location. The quadrilateral-shape of the cross-hole can assist in achieving a more uniform density of compactable material in the green body.

Abstract: The invention relates to a method for producing a ceramic proppant, including a step for preparing an original charge material, involving the grinding of source materials, particularly magnesium-containing materials, and auxiliary materials, thus producing a charge material, granulating the charge material so as to produce granules of a proppant precursor, and firing the granules of proppant precursor, thus producing proppant granules, wherein the method includes a step for pre-firing the magnesium-containing material in a reducing atmosphere. The invention also relates to a ceramic proppant produced via the indicated method.

Abstract: Provided is a porous plate-shaped filler that can be used as a material for a heat-insulation film having excellent heat insulation performance. In a porous plate-shaped filler 1 having a plate shape, an aspect ratio is 3 or higher, a minimum length is 0.5 to 50 ?m, and an overall porosity is 20 to 90%, and the porosity is lower in the circumferential part than in the center part. When this porous plate-shaped filler 1 of the present invention is contained in a heat-insulation film, the infiltration of a matrix into the filler is reduced, and thus the thermal conductivity can be lowered. Therefore, even a thin heat-insulation film can have a greater heat-insulation effect than before.

Abstract: A soil enhancement fertilizer composition that is delivered in a water-soluble pouch. The pouch contains specially composted and pulverized camelid manure, Mycorrhizal fungi, and yucca powder. The pouch is dissolved in water and stirred to release its contents and then the solution is poured on the soil and/or applied to the leaves of both indoor or outdoor container plants.

Abstract: Disclosed herein are a chromium compound represented by Formula 1a or 1b and a catalyst system including the same, exhibiting superior catalytic activity in an olefin trimerization reaction: [{CH3(CH2)3CH(CH2CH3)CO2}2Cr(OH)]??[Formula 1a] [{CH3CH2CH(CH2CH3)CO2}2Cr(OH)].

Abstract: A method for producing xylenes from a heavy reformate feed includes the steps of introducing the heavy reformate feed and a hydrogen feed to a dealkylation reactor, reacting the heavy reformate feed with the hydrogen gas in the presence of the dealkylation catalyst in the dealkylation reactor to produce a dealkylation effluent, introducing the dealkylation effluent to a splitter unit, separating the dealkylation effluent into a light gas stream, a toluene stream, a benzene stream, a C9 aromatics stream, a C10+ aromatics stream, and a mixed xylene stream in the splitter unit, introducing the toluene stream, the C9 aromatics stream, and a hydrogen stream into a transalkylation reactor, reacting the toluene stream and the C9 aromatics stream in the presence of the transalkylation catalyst to produce a transalkylation effluent, introducing the transalkylation effluent to the splitter unit, and separating the transalkylation effluent in the splitter unit.

Abstract: The present invention provides a process for the preparation of a (hydro)(chloro)fluoroalkene by contacting a reagent stream comprising a hydrochlorofluoroalkane with a catalyst in a reactor to dehydrochlorinate at least a portion of the hydrochlorofluoroalkane to produce a product stream comprising the (hydro)(chloro)fluoroalkene and hydrogen chloride (HCl), wherein the catalyst is selected from the group consisting of metal oxide catalysts, metal halide catalysts, zero-valent metal catalysts, carbon-based catalysts and mixtures thereof, and wherein (i) the catalyst is chlorinated prior to contacting it with the reagent stream comprising the hydrochlorofluoroalkane; and/or (ii) the contacting step is carried out in the presence of a HCl co-feed.

Abstract: There is provided an industrially advantageous and efficient method of producing a Z-isomer of HCFO-1224yd or HCFO-1223xd by isomerizing an E-isomer thereof. The method produces HCFO (Z-isomer) by causing specific HCFO (E-isomer) contained in a raw material composition to undergo an isomerization reaction under a condition where the HCFO (E-isomer) is isomerized.

Abstract: To provide a method for stably storing tetrafluoropropene filled in a container for e.g. storage or transportation, without occurrence of reaction such as polymerization. A method for storing tetrafluoropropene in a gaseous-liquid state composed of a gas phase and a liquid phase in a closed container, wherein the oxygen concentration (content) in the above gas phase is adjusted to at least 3 vol ppm and less than 3,000 vol ppm at a temperature of 25° C.

Abstract: The present invention relates to an apparatus and a method for preparing bisphenol A, and provides an apparatus and a method for preparing bisphenol A that can increase the energy efficiency of the entire process by utilizing an internal heat source.

Abstract: A method for purifying methacrylic acid, including mixing raw material methacrylic acid and methanol; precipitating a crystal of methacrylic acid from the mixed solution; and separating the crystal and mother liquor, wherein the raw material methacrylic acid and methanol are mixed so that a concentration of methanol in the mixed liquid is 3.0 to 3.75% by mass, and the crystal of methacrylic acid is precipitated from the mixed solution in a cooling crystallization vessel.

Abstract: A method for recovering a composition enriched in 3-hydroxypropionic acid from a fermentation broth comprising 3-hydroxypropionic acid and/or salts thereof comprises the steps of: (a) providing the fermentation broth having a pH of from about 2 to about 8 comprising: 3-hydroxypropionic acid and/or salts thereof, (b) acidifying the fermentation broth; (c) reducing the total sulfate ion and phosphate ion (d) distilling the resulting reduced ion aqueous solution and (e) recovering the product.

Abstract: A method for recovering a composition enriched in 3-hydroxypropionic acid by providing the fermentation broth, acidifying the fermentation broth; reducing the total sulfate ion and phosphate ion concentration of the resulting aqueous solution to produce a reduced ion aqueous solution; distilling the resulting reduced ion aqueous solution and recovering the resulting aqueous distillation product comprising 3-hydroxypropionic acid.

Abstract: The invention relates to a method for producing vinyl acetate, said method being characterized in that a) the gaseous product mixture leaving the reactor is cooled to a temperature of 100° C. to 120° C. using one or more heat exchangers, b) the thus obtained product mixture is supplied to a distillation column which is equipped with filling elements (pre-dehydration column), c) the pre-dehydration column head product which substantially contains wafer, vinyl acetate, and ethylene is cooled, and the condensate (head product condensate) produced in the process is separated into a water phase and an organic phase (vinyl acetate phase), which substantially comprises vinyl acetate, in a phase separator, d) at least 99 wt. % of the acetic acid contained in the product mixture is separated via the bottom of the pre-dehydration column, and the head product of the pre-dehydration column contains <0.1 wt.

Abstract: The present invention relates to a method for producing a substituted alkyl cycloalkanone, comprising the alkylation of a cycloalkanone with an alkene derivative in the presence of a metal oxide, where n is 2 to 20, m is 0 to 10, and R is a functional group.

Abstract: One object of the invention is to provide a method for preparing a 9,9-dialkoxy-7-nonynoate ester and (7E)-7,9-decadienoate ester, which are valuable as intermediates. The method for preparing a (7E)-7,9-decadienoate ester (5) comprises at least steps of: hydrolyzing a 9,9-dialkoxy-7-nonenoate ester (2), R3O(R2O)CHCH?CH(CH2)5CO2R1, to form a (7E)-9-oxo-7-nonenoate ester (3); and subjecting the (7E)-9-oxo-7-nonenoate ester (3) to a Wittig reaction with a triarylphosphonium methylide (4), Ar3P?CH2, to form the (7E)-7,9-decadienoate ester (5). The 9,9-dialkoxy-7-nonenoate ester may be prepared by, for example, reducing a 9,9-dialkoxy-7-nonynoate ester (1).

Abstract: Process for preparing aminated aromatic hydrocarbons that may be substituted comprising the steps of reacting an aromatic hydrocarbon with ammonia in the presence of a catalyst having a crystalline microporous structure wherein the catalyst comprises vanadium aluminophosphate molecular sieve (VAPO) and/or aluminophosphate molecular sieve (AlPO) and wherein the catalyst is preferably impregnated with nickel and/or copper, and wherein the aromatic hydrocarbon may be substituted.

Abstract: A family of amine mining collectors that uses alkoxylates allows for the easy adjustment of solubility and molecular weight useful because anionic and cationic mineral collectors require such varying degrees of solubility and molecular weight. The family of the present invention allows for the optimization of both parameters and an increase in collector efficiency.

Abstract: The disclosure provides compositions and methods that are useful in removing, lowering, or otherwise controlling hydrogen sulfide and mercaptans. The compositions and methods can be used in any industry where hydrogen sulfide poses problems, such as when dealing with crude oil based, natural gas based, and/or coal based products. In some embodiments, the compositions include one or more alkoxylated amino formaldehyde adducts.

Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Abstract: A method for preparing diphenol compounds includes adding a hydroxyphenyl carboxylic acid, a tyrosine ethyl ester, hydroxybenzotriazole hydrate and a solvent and stirring to produce a first solution. EDCI HCl is added to the first solution to produce a first mixture. Ethyl acetate is added to the first mixture to produce a second mixture. The second mixture is added to sodium chloride to produce a third mixture having layer separation. An aqueous layer is removed from the third mixture. The third mixture is extracted with reagents after the aqueous layer has been removed from the third mixture to produce a fourth mixture. Magnesium sulfate is added to the fourth mixture to produce a fifth mixture. The fifth mixture is filtered to produce filtrate. The filtrate is concentrated. Crystallization of the concentrated filtrate is induced. Methylene chloride is added to the crystallized filtrate to produce a solid product.

Abstract: There is provided as a biocide zinc or copper (II) salt having the general formula CH2?C(R1)COO-M-OCOC6H3R2R4, wherein M is Zn or Cu, R1 is selected from the group comprising hydrogen and methyl, R2 is selected from the group comprising hydrogen and OH, R4 is selected from the group comprising hydrogen, alkyl and SO2OH group.

Abstract: Compounds of formula (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compounds provide excellent interference of a binding of Nrf2 by Keap1, thereby activating Nrf2. The compounds have a potential anti-inflammatory activity and can be used to treat a plurality of inflammation-associated diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, gastroenteritis, rheumatoid arthritis, and the like.

Abstract: The invention concerns a synthesis process of a compound of the following formula (I) or one of the salts thereof, wherein R represents a COOH, CH2OH or CHO group, comprising the step according to which the but-3-ene-1,2-diol (BDO) is subjected to an oxidation in the presence of a catalyst, said catalyst comprising an active phase based on at least one noble metal selected from palladium, gold, silver, platinum, rhodium, osmium, ruthenium and iridium, and a support containing alkaline sites. The invention also concerns the application of this reaction to the preparation of bioavailable compounds of methionine used, in particular, in animal nutrition.

Abstract: This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.

Abstract: The subject of the invention is a novel process for the preparation of Carboprost tromethamine salt where alkylation the enone of the general formula (II) is carried out in the presence of a chiral auxiliary in aprotic solvent with a Grignard reagent. The methyl ester epimers of formula (VII) are separated by gravity silica gel chromatography and the salt formation is carried out by using solid tromethamine base.

Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

Abstract: The present invention relates to a novel process for producing of 2,3-dichloro-5-(trichloromethyl)pyridine by using PCl5 as chlorinating agent at elevated temperature and pressure.

Abstract: The present invention relates to a method for preparing 2,6-dichloropyridine with product purity greater than or equal to 99.0% through gas phase photochlorination of pyridine by using trifluoromethyl chlorobenzene as a solvent for reaction between pyridine and chlorine gas. Gasified pyridine and heated chlorine gas are enabled to continuously experience chlorination reaction under irradiation of ultraviolet light by using gasified pyridine and heated chlorine gas as starting materials and using heated trifluoromethyl chlorobenzene as a solvent, and a gas phase reaction product and the solvent are cooled to obtain pyridine chlorination solution. Advantages: firstly, it pioneers the precedent of direct and high-selectivity preparation of 2,6-dichloropyridine through gas phase photochlorination, and not only can the 2,6-dichloropyridine product with purity greater than or equal to 99.

Abstract: The present disclosure provides novel compounds, including compounds that bind to potassium channels, methods for their manufacture, and methods for their use, including their use to diagnose and/or assess traumatic brain injury and use to treat demyelinating diseases, and/or in vivo imaging of the central nervous system, and to diagnose and/or assess the progression of MS or other diseases.

Abstract: The present invention provides a method for producing a 2-aminonicotinic acid benzyl ester derivative. The method includes, as a step, reacting a 2-aminonicotinic acid derivative represented by the formula [I], wherein R1 represents a hydrogen atom or a C1 to C4 alkyl group and M represents an alkali metal, with a benzyl derivative represented by the formula [II], wherein R2 represents, for example, a hydrogen atom or a halogen atom, A represents, for example, a nitrogen atom, X represents a halogen atom, and Y represents, for example, an oxygen atom, in an aromatic hydrocarbon solvent in the presence of a phase transfer catalyst or a tertiary amine.

Abstract: The present invention provides a novel processes for preparation of methyl 3-(benzyloxy)-5-(2,4-difluorobenzylcarbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyiridine-2-carboxylate using novel intermediates.

Abstract: Disclosed are solid state forms of Netarsudil mesylate, processes for preparation thereof, uses thereof, and pharmaceutical compositions thereof.

Abstract: The present invention is directed to systems, devices and methods for identifying biopolymers, such as strands of DNA, as they pass through a constriction such as a carbon nanotube nanopore. More particularly, the invention is directed to such systems, devices and methods in which a newly translocated portion of the biopolymer forms a temporary electrical circuit between the nanotube nanopore and a second electrode, which may also be a nanotube. Further, the invention is directed to such systems, devices and methods in which the constriction is provided with a functionalized unit which, together with a newly translocated portion of the biopolymer, forms a temporary electrical circuit that can be used to characterize that portion of the biopolymer.

Abstract: The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Abstract: The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

Abstract: Methods and systems are disclosed relating to a lens system that allows for simultaneous focus of near and far-away images with one pair of glasses, heads-up-displays (HUDs), and the like, without the need to move the user's eyes. This lens system may be used in a HUD application, for example, where the user may focus on a display lens that may be approximately one inch from the eye to view computer-generated information such as altitude, temperature, directions, and the like, and simultaneously view the individual's surroundings. The lens system may include a liquid lens that when modulated may vary from a near-focus state to a far-focus state rapidly by using an electrowetting or piezoelectric hydraulic actuator. This variable rate lens may be multiplexed at a rate that allows both near and far-away images to appear in focus simultaneously through the advantageous use of a user's persistence of vision.

Abstract: The present disclosure relates to a preparation method of a trisodium AHU-377 and Valsartan co-crystal hydrate Form II. The preparation method comprises: firstly, preparing a clear solution of trisodium AHU-377 and Valsartan, the solvent of the clear solution comprises an anti-solvent and a good solvent of the target product Form II, and the boiling point of the good solvent is lower than that of the anti-solvent; secondly, evaporating the solution under vacuum to remove the good solvent and water from the system; and finally, optionally adding seed crystals of Form II or not and replenishing a mixture of water and a carrier solvent for stirring for crystallization. The method of the present disclosure can prepare Form II successfully, and the process is consistent and controllable. The obtained Form II product has high chemical purity, crystalline purity and good flowability; and the process can be scaled up, and meets the requirements of large-scale production.

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

Abstract: The present invention relates to the use of novel oxadiazoles of the formula I or an N-oxide and/or their agriculturally useful salts for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful fungi, which process comprises treating the fungi or the materials, plants, the soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula I or an N-oxide or an agriculturally acceptable salt thereof; and to agrochemical compositions comprising at least one such compound and to agrochemical compositions further comprising seeds.

Abstract: Disclosed are compounds of Formula A-1, or a salt thereof: Formula A-1, where J, K, Q and R1 are as defined herein, which compounds have properties for inhibiting sodium ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-1 or their salts, and methods of treating pain (e.g. chronic pain), or cough or itch disorders using the same.

Abstract: The invention provides compositions and methods useful for the treatment of Friedreich's ataxia. In some embodiments, the invention provides compositions and methods useful for inhibiting the ubiquitination of frataxin.

Abstract: The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same.

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease.

Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.

Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.

Abstract: Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.